Vivus Announces Promising Results of Avanafil Nitrate Interaction Study

Vivus has announced results of a clinical pharmacology study conducted to evaluate the hemodynamic responses (blood pressure and heart rate) to glyceryl trinitrate (GTN) in subjects pretreated with placebo, avanafil (Vivus' investigational PDE5 inhibitor) or sildenafil citrate (Viagra).

Results of the 101-patient study of healthy males showed that there was a trend at all time points evaluated toward a greater decrease in the mean maximal standing systolic blood pressure over a 12-hour period following GTN administration in subjects pretreated with sildenafil as compared to those pretreated with avanafil or a placebo.

Avanafil is Vivus' investigational oral phosphodiesterase Type 5 (PDE5) inhibitor being developed for the treatment of erectile dysfunction.